Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm for which a standardized treatment approach has yet to be established. The prevailing therapeutic strategy typically involves resection followed by adjuvant chemotherapy or radiation. This case report details the long-term follow-up of a 59-year-old Chinese male diagnosed with gallbladder FDCS and liver metastases. The patient received a combination therapy of sintilimab and anlotinib, resulting in a substantial partial response (PR) lasting for a noteworthy duration of 30 months. Notably, this is the first documented instance of gallbladder FDCS with liver metastases being treated with PD-1 antibody and antiangiogenic agents as first-line therapy. These findings suggest that this treatment regimen may offer a potential therapeutic option for patients with gallbladder FDCS and liver metastases, with a duration of PR lasting up to 30 months.
[1]Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Clin Pharm Ctr,Dept Pharm, Hangzhou 310014, Peoples R China.
[2]Key Lab Endocrine Gland Dis Zhejiang Prov, Hangzhou 310014, Peoples R China.
[3]Kunming Med Univ, Kunming Yanan Hosp, Dept Pharm, Yanan Affiliated Hosp, Kunming 650051, Yunnan, Peoples R China.
[4]Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Dept Pathol, Hangzhou 310014, Peoples R China.
[5]Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Canc Ctr, Affiliated Peoples Hosp,Dept Oncol, Hangzhou 310014, Peoples R China.
[6]Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Clin Pharm Ctr, Dept Pharm,Peoples Hosp, 158 Shangtang Rd, Hangzhou 310014, Peoples R China.
[7]Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Oncol, Peoples Hosp, 158 Shangtang Rd, Hangzhou 310014, Peoples R China.
(8.0+极速模式)